Answers are grounded in this paper and cite their sources.
Mavacamten is a FDA-approved small-molecule therapeutic designed to regulate cardiac function at the sarcomere level by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin toward ordered
No takes yet. Share an insight, caveat, or question.
Ma et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: